title: Sensitivity of 9L gliosarcomas to photodynamic therapy.
abstract: Photodynamic therapy (PDT) has been used clinically for the treatment of malignant brain gliomas. However, the efficacy of this treatment to date has remained equivocal. This study focused on determining the sensitivity of 9L glio sarcoma in Fischer 344 rats to PDT with increasing doses of 632 nm light and making a comparison of the responses of normal and tumor tissue in the brain at these doses. This sensitivity was then correlated with the concentrations of Photoforin present in these tissues at the time of treatment. Our study indicates that the level of Photofrin in the tumor was 13 times that present in normal brain 48 h after injection. However, this selective localization of the photosensitizer was not reflected in a selective tissue response to PDT. There was minimal tumor response to a dose of 35 J cm-2, which has been reported previously to cause necrosis to the normal brain. Increasing energy dose levels resulted in an increased tumor response to PDT; however, normal tissue remained more sensitive than tumor tissue at all energy dose levels examined. These data indicate that, although Photofrin is retained to a significantly higher degree in the tumor than in the normal brain tissue, the normal brain is more sensitive than the tumor to PDT under the conditions outlined in this study.
authors.affiliation: Henry Ford Health Sciences Center, Neurology Department, Detroit, Michigan 48202, USA.
authors.forename: M
authors.initials: M
authors.lastname: Chopp
authors.forename: M O
authors.initials: MO
authors.lastname: Dereski
authors.forename: L
authors.initials: L
authors.lastname: Madigan
authors.forename: F
authors.initials: F
authors.lastname: Jiang
authors.forename: B
authors.initials: B
authors.lastname: Logie
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018316:Gliosarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017324:Hematoporphyrin Derivative / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D011836:Radiation Tolerance; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000970:Antineoplastic Agents; D017319:Photosensitizing Agents; D017324:Hematoporphyrin Derivative